Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey, ANRS EN19)

HIV Med. 2009 May;10(5):282-9. doi: 10.1111/j.1468-1293.2008.00686.x. Epub 2009 Feb 15.

Abstract

Background: More than 10 years after the introduction of combination antiretroviral therapy (cART), we examined the trend in the proportion of deaths caused by end-stage liver disease (ESLD) in HIV-infected adults in France between 1995 and 2005.

Design and methods: In 2005, 34 departments prospectively recorded all deaths in HIV-infected patients who were followed in those departments (around 24 000).

Results: were compared with those of four previous cross-sectional surveys conducted since 1995 using the same methodology. Results Among 287 reported deaths in 2005, 100 (35%) were related to AIDS, and 48 (17%) to ESLD. Three out of four patients who died from ESLD-related causes had chronic hepatitis C. Excessive alcohol consumption was reported in approximately half of the patients (48%). At death, 62% of patients had undetectable HIV viral load and the median CD4 count was 237 cells/microL. From 1995 to 2005, the proportion of deaths caused by ESLD increased from 2 to 17% (P<0.001). The proportion of deaths caused by hepatocellular carcinoma increased from 5% in 1995 to 25% in 2005 (P=0.0337).

Conclusions: Over the 10 years from 1995 to 2005, the proportion of deaths caused by hepatitis C virus-related ESLD has increased in HIV-infected patients. ESLD is currently a leading cause of death in this population, with hepatocellular carcinoma representing a quarter of liver-related deaths. Recommendations for the detection of hepatocellular carcinoma should be strictly applied in these patients.

Publication types

  • Multicenter Study

MeSH terms

  • Acquired Immunodeficiency Syndrome / complications
  • Acquired Immunodeficiency Syndrome / mortality
  • Adult
  • Aged
  • Alcohol Drinking / mortality
  • Antiretroviral Therapy, Highly Active
  • CD4 Lymphocyte Count
  • Carcinoma, Hepatocellular / complications
  • Carcinoma, Hepatocellular / mortality*
  • Cause of Death / trends
  • Cross-Sectional Studies
  • Female
  • France / epidemiology
  • HIV Infections / complications
  • HIV Infections / mortality*
  • Hepatitis C, Chronic / complications
  • Hepatitis C, Chronic / mortality*
  • Humans
  • Liver Cirrhosis, Alcoholic / complications
  • Liver Cirrhosis, Alcoholic / mortality
  • Liver Neoplasms / mortality*
  • Male
  • Middle Aged
  • Prospective Studies
  • alpha-Fetoproteins / analysis

Substances

  • alpha-Fetoproteins